Sir,

The single-stranded RNA genome of the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) about 29.9 kb in length and encoding about 9860 amino acids, was annotated to possess 14 open reading frames (ORFs) and 27 proteins[@ref1][@ref2]. The *orf*1ab and *orf*1a genes at the 5´-terminus of the genome encode the pp1ab and pp1a proteins, respectively, together form 15 non-structural proteins (nsps), nsp1-nsp10 and nsp12-nsp16. The 3´-terminus of the genome encodes four structural proteins, the spike surface glycoprotein (*S*), the small envelope protein (*E*), membrane protein (*M*) and nucleocapsid protein (*N*). There are eight accessory proteins denoted as 3a, 3b, p6, 7a, 7b, 8b, 9b and ORF14[@ref2].

The epidemiology of the SARS-CoV-2 since its emergence in December 2019 has been ever expanding, with increase in the number of cases and its spread globally[@ref3][@ref4]. The number of SARS-CoV-2 cases in India as on March 31, 2020 was 1,071, with mortality crossing 29[@ref4]. In this context, it is vital to understand the genetic nature of circulating SARS-CoV-2. In India, as per the guideline of the Ministry of Health and Family Welfare, suspected samples of SARS-CoV-2 were collected and tested at the designated Viral Research and Diagnostic Laboratories (VRDL)[@ref5]. As a part of this activity, a total of 15 SARS-CoV-2 positive specimens were obtained during the first week of March 2020, from Italian tourists and travellers from Italy and their contact cases in India. Further, in an effort to screen Indian nationals in Iran to enable their evacuation, during March 5 to 17, 2020, throat swabs were collected from 1,920 individuals; of whom 281 were positive. In addition, a team of Indian doctors visited Italy and collected a total of 380 swabs of Indian citizens; of whom four positive specimens were identified. In an earlier study, the authors identified the first three cases of SARS-CoV-2 in Kerala, India, as imported cases from Wuhan, China, and presented the first two full-genome sequences along with the potential B-cell and T-cell epitopes on the spike protein[@ref6]. Further, in another study, the SARS-CoV-2 viruses were isolated in Vero CCL-81 cells[@ref7]. The present study was undertaken to understand and compare the genetic makeup of representative samples of the imported cases of SARS-CoV-2 to India from Wuhan, China, those of Italian tourists in India and the Indians evacuated from Iran and Italy.

Throat swab/nasal swab specimens collected from the 1,920 individuals in Iran were tested at the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV) Pune, using real-time reverse transcription-polymerase chain reaction (RT-PCR) protocols to detect *RdRp* (1), *RdRp* (2), *E* and *N* genes as described elsewhere[@ref8]. Next-generation sequencing (NGS) was performed on a total of 41 SARS-CoV-2 positive clinical samples from Italy and Iran. [Table I](#T1){ref-type="table"} presents the details of the full genomes obtained (n=19) as a part of this study as well as the two earlier genomes retrieved from the Kerala samples (n=2) from those who had the travel history from China[@ref6][@ref7].

###### 

Cycle threshold (Ct) values of real-time reverse transcription-polymerase chain reaction (RT-PCR) for the *E* gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) along with the per cent of the reads mapped and the genome size recovered for the clinical samples

  Sample ID                     Travel history/details                                                                        Ct value of *E* gene for clinical samples   Per cent of relevant reads   Genome length (bp)   GISAID ID
  ----------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------- ---------------------------- -------------------- ----------------
  hCoV-19/India/1-27/2020^\*^   Wuhan, China travel history of Indian citizens (Group A)                                      34.5                                        0.36                         29,854               EPI_ISL_413522
  hCoV-19/India/1-31/2020^\*^   28.98                                                                                         0.80                                        29,851                       EPI_ISL_413523       
  hCoV-19/India/1073/2020       Specimens collected at Iran from Indian citizens (Group B)                                    25                                          1.53                         29,855               EPI_ISL_421662
  hCoV-19/India/1093/2020       23                                                                                            0.10                                        29,847                       EPI_ISL_421663       
  hCoV-19/India/1100/2020       23                                                                                            0.79                                        29,862                       EPI_ISL_421664       
  hCoV-19/India/1104/2020       22                                                                                            34.88                                       29,890                       EPI_ISL_421665       
  hCoV-19/India/1111/2020       22                                                                                            3.36                                        29,861                       EPI_ISL_421666       
  hCoV-19/India/1115/2020       22                                                                                            3.04                                        29,864                       EPI_ISL_421667       
  hCoV-19/India/1125/2020       25                                                                                            0.18                                        29,873                       EPI_ISL_421668       
  hCoV-19/India/1616/2020       23                                                                                            0.60                                        29,857                       EPI_ISL_421669       
  hCoV-19/India/1621/2020       18                                                                                            5.28                                        29,860                       EPI_ISL_421671       
  hCoV-19/India/1644/2020       22                                                                                            1.23                                        29,855                       EPI_ISL_421672       
  hCoV-19/India/1652/2020       24                                                                                            0.17                                        29,847                       EPI_ISL_424363       
  hCoV-19/India/3118/2020       Indian contacts of an Indian citizen having travel history to Italy (Group C)                 24                                          3.30                         29,857               EPI_ISL_424364
  hCoV-19/India/3239/2020       20                                                                                            22.58                                       29,862                       EPI_ISL_424365       
  hCoV-19/India/770/2020^‡^     Italian tourists who arrived in Delhi, India and an Indian contact of the cohort (Group D)    18                                          93.08                        29,862               EPI_ISL_420545
  hCoV-19/India/773/2020^‡^     25.1                                                                                          19.98                                       29,858                       EPI_ISL_420549       
  hCoV-19/India/777/2020^‡^     22.1                                                                                          26.93                                       29,856                       EPI_ISL_420551       
  hCoV-19/India/781/2020^‡^     22.1                                                                                          35.47                                       29,871                       EPI_ISL_420553       
  hCoV-19/India/31/2020         Close contacts in Agra, of an infected Delhi-based person who returned from Italy (Group E)   25                                          2.13                         29,860               EPI_ISL_426179
  hCoV-19/India/32/2020^‡^      16                                                                                            88.50                                       29,903                       EPI_ISL_420555       

GISAID, Global Initiative on Sharing All Influenza Data

*Source*: ^\*^Ref. [@ref6], ^‡^Ref. [@ref7]

Multiple sequence alignment of 21 full genomes obtained and 1563 full-genome sequences (Supplementary Table (available from *<http://www.ijmr.org.in/articles/2020/151/2/images/IndianJMedRes_2020_151_2_255_283159_sm5.pdf>*)) available at the Global Initiative on Sharing All Influenza Data (GISAID) database (as of March 26, 2020) was carried out in MAFFT v.7.450[@ref9]. The phylogenetic tree was constructed using MEGA v.6[@ref10], employing the neighbour-joining method with the composite likelihood method and 1000 bootstrap replications. An initial tree was constructed based on a total of 1586 sequences. This tree was used to reduce the dataset to 121 sequences, on the basis of country and the genetic variant identified based on the GISAID classification. Comparison of the sequences of this study with respect to the Wuhan Hu-1 reference strain was done to identify unique mutations, if any.

Phylogenetic trees based on full-genome sequences deposited and available at GISAID revealed the diversification and the clustering of sequences into groups, based on the genetic variants. Specific amino acid substitutions in the nsp3 region, spike protein and ORF8, in general, lead to the formation of V, G and S genetic variants/clades, respectively. The S clade corresponds to the C28144T nucleotide polymorphism that results in a non-synonymous substitution Leu84Ser in ORF8. Clades V, G and a group of unclassified strains possess mainly C28144 and are referred to as the L type[@ref11]. The phylogenetic analyses of the study strains and the other global sequences revealed that the SARS-CoV-2 sequences derived from Italy (n=8) in this study, clustered in clade G, while the SARS-CoV-2 sequences (n=11) of Indians evacuated from Iran belonged to the unclassified group which also included one of the SARS-CoV-2 sequences imported from Wuhan (hCoV-19/India/1-27/2020) ([Figure](#F1){ref-type="fig"}). The other sequences imported from Wuhan (hCoV-19/India/1-31/2020) possessed Leu84Ser in ORF8b, classifying it in clade S.

![Phylogenetic tree of selected representative full-genome sequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived from coronavirus disease 2019 positive patients\' clinical samples who had travel history of Wuhan, China, Italy and Iran by neighbour-joining method. Strains sequenced at ICMR-NIV are shown in magenta colour. The clades as per Global Initiative on Sharing All Influenza Data (GISAID) nomenclature are indicated in blue (clade G), red (clade V), green (clade S) and black (unclassified).](IJMR-151-255-g001){#F1}

The sequences of Italy origin were noted to segregate into at least two subgroups. The percentage nucleotide divergence (PND) within these sequences was found to be 0.01 per cent. The SARS-CoV-2 sequences from the Italian tourists (n=6) showed relatedness to other European SARS-CoV-2 sequences from Scotland, Finland, England, Spain, Ireland and the Czech Republic along with a Shanghai, China, strain as the outgroup (Figure). Two other sequences (hCoV-19/India/3118/2020 and hCoV-19/India/3239/2020) clustered more closely with sequences from Belgium and Switzerland. The two sequences (hCoV-19/India/31/2020 and hCoV-19/India/32/2020) from the Agra contacts of the Italy-returned Delhi based individuals were more distinct and showed clustering in a strongly supported subgroup consisting of strains from Brazil and the European countries including Switzerland, Germany, France, Hungary and The Netherlands.

The variable amino acid sites based on the alignment of the 21 sequences of this study with respect to Wuhan Hu-1 strain are shown in [Table II](#T2){ref-type="table"}. All the Italy-origin sequences possessed the substitution D7711G/D614G in the S protein, characteristic of the G clade, along with another mutation P4715L (nsp12-323) that is also shared with many other countries. Mutation S1515F (nsp3-697) was specific to the Italian cohort strain; D8726G (M-3) was specific to hCoV-19/India/3118/2020 and hCoV-19/India/3239/2020 (Indian contacts of an Indian citizen having travel history to Italy), similar to sequences from Scotland, Belgium, Finland, Switzerland and England. The mutations, R9455K and G9456R (N-203 and 204), were found to be specific to the two strains, hCoV-19/India/31/2020 and hCoV-19/India/32/2020 but shared with a few more countries. A recent study has identified the earliest Italian importation of SARS-CoV-2 to a case from Shanghai, China, and has also identified at least two circulating variants in Italy[@ref12]. Thus, it is likely that the former strain (Italian cohort) has its origin from China, whereas the latter strain (contacts in Agra, n=2) appears to have been from a European cluster involving an entry into Germany that preceded the first cases in Italy by almost a month[@ref12][@ref13].

###### 

Variable amino acid positions in the Indian full-genome sequences

  Amino acid position in genome             207   378   476   671   1515   2079   2144   2796   3606   4715   4798   5538   7505   7535   7711   8027   8726   9082   9214   9455   9456
  ----------------------------------------- ----- ----- ----- ----- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  NC 045512 Wuhan-Hu-1                      R     V     I     I     S      P      P      M      L      P      A      T      R      S      D      A      D      V      L      R      G
  hCoV-19/India/1-27/2020\|EPI ISL 413522   .     .     .     T     .      .      S      .      .      .      V      .      I      .      .      .      .      .      .      .      .
  hCoV-19/India/1-31/2020\|EPI ISL 413523   .     .     V     .     .      L      .      .      .      .      .      I      .      .      .      V      .      .      S      .      .
  hCoV-19/India/1073/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      F      .      .      .
  hCoV-19/India/1093/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      F      .      .      .
  hCoV-19/India/1100/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      F      .      .      .
  hCoV-19/India/1104/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/1111/2020                   .     I     .     .     .      .      .      .      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/1115/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      F      .      .      .
  hCoV-19/India/1125/2020                   .     I     .     .     .      .      .      .      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/1616/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/1621/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/1644/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/1652/2020                   C     I     .     .     .      .      .      I      F      .      .      .      .      .      .      .      .      .      .      .      .
  hCoV-19/India/3118/2020                   .     .     .     .     .      .      .      .      .      L      .      .      .      .      G      .      G      .      .      .      .
  hCoV-19/India/3239/2020                   .     .     .     .     .      .      .      .      .      L      .      .      .      .      G      .      G      .      .      .      .
  hCoV-19/India/770/2020                    .     .     .     .     F      .      .      .      .      L      .      .      .      .      G      .      .      .      .      .      .
  hCoV-19/India/773/2020                    .     .     .     .     F      .      .      .      .      L      .      .      .      .      G      .      .      .      .      .      .
  hCoV-19/India/777/2020                    .     .     .     .     F      .      .      .      .      L      .      .      .      .      G      .      .      .      .      .      .
  hCoV-19/India/781/2020                    .     .     .     .     F      .      .      .      .      L      .      .      .      .      G      .      .      .      .      .      .
  hCoV-19/India/31/2020                     .     .     .     .     .      .      .      .      .      L      .      .      .      .      G      .      .      .      .      K      R
  hCoV-19/India/32/2020                     .     .     .     .     .      .      .      .      .      L      .      .      .      .      G      .      .      .      .      K      R

Wuhan Hu-1 strain of severe acute respiratory syndrome coronaviruses 2 (SARS-CoV-2) is used as the reference strain. Strains and mutations specific to China, Iran and Italy are shown in orange, violet and brown colour, respectively. In case of Iran and Italy, only those amino acid sites are shown where at least two of the sequences share the same mutation. R, arginine; V, valine; I, isoleucine; S, serine; P, proline; M, methionine; L, leucine; A, alanine; T, threonine; D, aspartic acid; G, glycine; C, cysteine; F, phenylalanine; K, lysine

Analysis of the strains from the SARS-CoV-2 positives in Iran ([Figure](#F1){ref-type="fig"}) showed that these sequences (n=11) clustered with other strains having a global spread inclusive of Canada, USA, several European countries, New Zealand, Australia and Southeast Asian countries noted in this group (moderate support of 64%). The PND among these study sequences was found to be 0.24 per cent. Common mutations shared among SARS-CoV-2 sequences in the group included R207C (nsp2-27), V378I (nsp2-198), M2796I (nsp4-33) and L3606F (nsp6-37). A mutation V9082F (ORF7a-74) was unique to four of the study sequences (hCoV-19/India/1073/2020, hCoV-19/India/1093/2020, hCoV-19/India/1115/2020 and hCoV-19/India/1100/2020) that clustered with a strain from Kuwait, KU12. The KU12 strain was also noted to possess this mutation. To date, there are no other sequences from Iran in the GISAID database. However, a phylogenetic study[@ref14] of full-genome sequences has identified distinct SARS-CoV-2 link to travellers returning from Iran to Australia and New Zealand. Some of these representative sequences were included in this study as well.

In terms of the overall divergence of SARS-CoV-2, the strains in this study were 99.97 per cent identical to the earliest strain Wuhan Hu-1. However, it is vital to track the evolutionary dynamics of the strains *vis-à-vis* the strains circulating globally and monitor any specific changes in the functional sites of the major viral proteins.

Delineation of circulating strains into three major evolving clades has been reflected in GISAID, with clade G apparently being one of the dominant ones. From the start of the pandemic, severity or transmission patterns have not been associated with any clade in particular. A limitation of this study was the non-availability of full genomes from other parts of India. This would enable a pan-India comparison of the circulating strains in the country. Overall, the present study revealed genetic variants in India that were similar to strains circulating in the specific regions of their origin. Continued surveillance of SARS-CoV-2 strains in India is warranted to get the complete picture of all circulating strains and identify changes that could be associated with increased virulence.
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